Pharmaceutical AI runs on biological data — protein structures, genomic sequences, assay results — and the legal status of that data is unsettled in ways that cloud-infrastructure launches do not typically resolve. The simultaneous appearance of data provenance Q&As across Bluesky's health-law, AI-law, and M&A legal feeds [2][3] is not coincidental amplification; it is three professional communities independently arriving at the same gap in AWS's announcement. Memorial Sloan Kettering's use of the platform to accelerate provides a concrete early case, but it also raises the question that…